Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Harmony Biosciences Holdings (HRMY – Research Report) today and set a price target of $64.00. The company’s shares closed last Tuesday at $50.60.
According to TipRanks.com, Suvannavejh is a 3-star analyst with an average return of 1.0% and a 49.0% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Intra-Cellular Therapies, and Bioxcel Therapeutics.
Currently, the analyst consensus on Harmony Biosciences Holdings is a Strong Buy with an average price target of $59.50.
Based on Harmony Biosciences Holdings’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $85.31 million and net profit of $21.49 million. In comparison, last year the company earned revenue of $59.67 million and had a net profit of $7.39 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs.
Read More on HRMY: